Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas Research ArticlesJamison WrightSeptember 26, 2017 Facebook0 Twitter Tumblr 0 Likes